Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Vycor Medical (VYCO) EBITDA Margin (2016 - 2025)

Vycor Medical has reported EBITDA Margin over the past 16 years, most recently at 15.04% for Q4 2025.

  • Quarterly EBITDA Margin fell 1356.0% to 15.04% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 3.89% through Dec 2025, up 286.0% year-over-year, with the annual reading at 3.89% for FY2025, 286.0% up from the prior year.
  • EBITDA Margin was 15.04% for Q4 2025 at Vycor Medical, down from 0.96% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 14.17% in Q2 2023 and troughed at 82.13% in Q1 2021.
  • The 5-year median for EBITDA Margin is 12.06% (2025), against an average of 18.13%.
  • Year-over-year, EBITDA Margin skyrocketed 9998bps in 2021 and then plummeted -3815bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 68.34% in 2021, then surged by 37bps to 42.96% in 2022, then grew by 30bps to 30.19% in 2023, then surged by 95bps to 1.48% in 2024, then plummeted by -916bps to 15.04% in 2025.
  • Per Business Quant, the three most recent readings for VYCO's EBITDA Margin are 15.04% (Q4 2025), 0.96% (Q3 2025), and 4.81% (Q2 2025).